Theorizing an enhancement of the protection and of the justiciability of biorights in the European Union

The attention given to bioethics and biolaw has grown throughout the decades in the framework of the European Union, since the first steps were taken in the field of medical products, with the adoption of Council Directive 65/65/EEC. Moving from the EU Treaties, which provide the legal bases for bio...

Descripción completa

Detalles Bibliográficos
Autor: Fanni, Simona
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/134147
Acceso en línea:https://hdl.handle.net/11441/134147
https://doi.org/10.12795/IETSCIENTIA.2021.i01.13
Access Level:acceso abierto
Palabra clave:Court of Justice of the European Union
European Court of Human Rights
Biorights
Human embryo research
Surrogacy
Abortion
Cross-fertilization
Tribunal de Justicia de la Unión Europea
Tribunal Europeo de Derechos Humanos
Bioderechos
Investigación con embriones humanos
Maternidad subrogada
Fertilización cruzada jurisprudencial
Descripción
Sumario:The attention given to bioethics and biolaw has grown throughout the decades in the framework of the European Union, since the first steps were taken in the field of medical products, with the adoption of Council Directive 65/65/EEC. Moving from the EU Treaties, which provide the legal bases for bioethics and biorights as well as for some potentially competing principles and interests, as the four freedoms, this study adopts a human rights-based approach to biolaw and assesses the jurisprudence of the Court of Justice of the European Union and the role of the Charter of Fundamental Rights of the European Union (CFR) from this viewpoint. Comparison is made with the jurisprudence of the European Court of Human Rights, for analysing viable paths of judicial dialogue and cross-fertilization as a response to the challenges posed by biolaw, in line with Article 52(3) of the CFR.